| Name | Title | Contact Details |
|---|
Juventas Therapeutics is a private clinical-stage company developing novel therapies for ischemic cardiovascular disease. The company`s lead product` JVS-100` is a non-viral plasmid that encodes for stromal cell-derived factor-1 (SDF-1). SDF-1 has been shown to significantly increase end-organ function following tissue injury by promoting cell survival` recruiting endogenous stem cells to the damaged region` and promoting new blood vessel growth. The SDF-1 repair pathway is well conserved throughout end-organ systems providing the opportunity to impact a broad range of diseases. Target cardiovascular clinical indications address large markets with high unmet medical need and significant market potential. Juventas is currently enrolling multiple clinical trials to test therapy efficacy in heart failure and critical limb ischemia patients.
Introducing enosix – an all-in-one SAP Integration Solution that provides fast SAP & Salesforce integrations between front-end platforms and SAP ERP systems.
The ByteChek platform makes compliance suck less as the only platform that includes automated SOC 2 reporting and automated evidence collection.
ByteDance or Beijing ByteDance Technology Co Ltd. ByteDances core product, Toutiao, is a popular content platform in China.
Enosis Solutions is a Pittsburgh, PA-based company in the Software and Internet sector.